Researchers require sensitive and reproducible methods to understand the biological mechanisms underlying disease pathogenesis and to develop novel therapeutics. One of the most popular approaches to biomarker discovery is through single-cell and low-input RNA-seq technologies, many of which rely on 3′ end-counting methods. While these methods allow for detection of gene expression signatures in single cells, they are unable to detect important biomarkers such as single nucleotide polymorphisms (SNPs), isoforms, and gene fusions, which can only be identified using full-length RNA-seq methods.
To improve the quality of biomarker discovery workflows, it is critical to efficiently maximize laboratory operations, from library prep through sequencing and analysis. Takara Bio is well positioned, with its portfolio of industry-leading single-cell and low-input library preparation solutions, to support customers in uncovering novel biomarkers in oncology and infectious disease. With streamlined workflows from samples through sequencing data analysis, SMART-Seq technology delivers more data from every sample. This facilitates the discovery of novel RNA isoforms, gene fusions, and SNPs, leading to new biological discoveries.
Biomarker discovery also benefits from faster sequencing turnaround times. Singular Genomics has developed an innovative benchtop sequencer, the G4 Sequencing Platform, that leverages a 4-color rapid sequencing by synthesis (SBS) chemistry with advanced optics and fluidics engineering to provide single-day turnaround times across all applications. By combining fast run times and the ability to run up to 4 flow cells, with 16 independently addressable lanes, the G4 enables highly efficient laboratory operations.
Three sets of experiments performed on control RNA and single cells show that the combined Takara Bio and Singular Genomics workflow yields similar sequencing metrics and data quality as industry-standard sequencing platforms. These results show that researchers now have access to a fast, accurate, and cost-effective solution to power their biomarker discovery research.